CJC-1295 +Ipamorelin
C$91.99
For Research Use Only
CJC-1295 (Mod GRF 1-29) and Ipamorelin are synthetic peptides that stimulate growth hormone (GH) secretion via complementary mechanisms.
- CJC-1295 (Mod GRF 1-29): A modified truncated analog of GHRH (1-29) that functions as a GHRH receptor agonist. Its tetrasubstitution and conjugation with a drug affinity complex (N‑epsilon‑3‑maleimidopropionamide) enhance pharmacokinetics through plasma protein binding.
- Ipamorelin: A pentapeptide analog of ghrelin, it activates GHS-R1a receptors in the pituitary to promote GH release.
- GHRP-2: A GH secretagogue that further augments GH secretion via similar endocrine pathways.
Combined, these peptides may synergistically optimize GH modulation.
This peptide blend is provided for research and laboratory use only. Please review and adhere to our Terms and Conditions before ordering.
Quantity
Molecular Makeup
Chemical Composition
- CJC-1295 (Mod GRF 1‑29): C₁₅₂H₂₅₂N₄₄O₄₂; MW: 3367.9 g/mol
- Ipamorelin: C₃₈H₄₉N₉O₅; MW: 711.9 g/mol (also known as Ipamorelin Acetate, IPA)
- GHRP‑2: C₄₅H₅₅N₉O₆; MW: 817.9 g/mol (also known as Pralmorelin or Growth Hormone‑Releasing Peptide‑2)
Research Insights
Research and Clinical Studies
- GH Deficiency & Hormonal Modulation:
Clinical trials in GH‑deficient subjects indicate that the CJC‑1295, Ipamorelin, and GHRP‑2 blend markedly elevates GH secretion via dual activation of the pituitary and hypothalamic pathways. These peptides appear to modulate not only GH but also associated parameters such as food intake, cardiac tone, and sleep.
- Food Intake:
In controlled studies, administration of GHRP‑2 increased food consumption by approximately 36% compared to controls. Ipamorelin, through its affinity for ghrelin receptors, may further promote appetite, weight gain, and elevated serum leptin levels, whereas CJC‑1295 appears neutral with respect to feeding behavior.
- Bone Mass:
Murine models evaluated by DXA and pQCT demonstrate that Ipamorelin enhances bone mineral content (BMC) in regions such as the femur, tibia, and L6 vertebrae. Increases in cortical BMC seem attributable to an expanded bone cross-sectional area rather than changes in volumetric bone mineral density (BMD).
- Muscle Anabolism:
In GHRH‑deficient (GHRHKO) models, CJC‑1295 facilitates the maintenance of lean mass and normal somatic growth. Concurrently, Ipamorelin improves nitrogen balance, decreasing catabolic markers, and increasing pituitary and GH mRNA expression, suggesting a synergistic anabolic effect on muscle tissues.